54-36-4 | Metyrapone

Chemical type

• Steroidogenesis inhibitor

^[1]

• Pharmacological inhibitor (11β-hydroxylase inhibitor)

^[2]

Key properties

• Selectively inhibits CYP11B1 and CYP11B2
• No effect on CYP7A
• Less potent inhibition of CYP3A4
• Can increase deoxycorticosterone and androgen levels (hypokalemia, hypertension, edema risks)
• Considered second-line in women due to hyperandrogenic effects
• Less potent than osilodrostat
• Shorter half-life, more frequent dosing

^[1]

• Inhibits the enzyme 11β-hydroxylase, which is crucial for the final step of cortisol synthesis.

^[2]

• Medical therapy for Cushing syndrome
• Alternative to osilodrostat

^[1]

• Experimental research: Used as a pharmacological treatment in zebrafish larvae to block cortisol production. This allowed researchers to rule out the involvement of endogenous cortisol in the observed effects of CRH on leukocyte migration.

^[2]

Classification by use

• Medications for Cushing syndrome
• Steroidogenesis inhibitors

^[1]

• Research chemical (pharmacological tool in endocrinology)

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] Osilodrostat for Cyclic Cushing Disease, AACE Endocrinology and Diabetes, Volume 13, Issue 1, January–February 2026, Pages 17-21
2. [Cite:2] Corticotropin-releasing hormone enhances the responsivity of macrophages to inflammation in zebrafish, General and Comparative Endocrinology, Volume 373, October 2025, 114815